Talk:Bioblast 2022: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 56: | Line 56: | ||
|- | |- | ||
|- | |- | ||
| || || 14:00|| || | | || || 14:00|| [[Sobotka 2022 Abstract Bioblast| The Crabtree effect and clinical nutrition]] || [[Sobotka Lubos]] | ||
|- | |- | ||
|- | |- | ||
| || || 14:15 || [[ | | || || 14:15 || [[Moreno-Sanchez 2022 Abstract Bioblast |Estimation of energy pathway fluxes in cancer cells- beyond the Warburg effect]] || [[MX Mexiko City Moreno-Sanchez R]] | ||
|- | |- | ||
|- | |- | ||
| || || 14:30 || || | | || || 14:30 || [[Heimler 2022 MitoFit|Platelet bioenergetics are associated with resting metabolic rate and exercise capacity in older women]] || [[Molina Anthony JA]] | ||
|- | |- | ||
|- | |- | ||
| || || 14:45 || ::::## [[Neuzil | | || || 14:45 || ::::## [[Neuzil 2022 Abstract Bioblast|Metabolic switch utilizing ammonia supports proliferation in regenerating liver]] || [[Neuzil Jiri]] | ||
|- | |- | ||
|- | |- | ||
Line 71: | Line 71: | ||
|- | |- | ||
|- | |- | ||
| || || 15:00 || || | | || || 15:00 || [[Arandarcikaite 2022 Abstract Bioblast|Hypoxia-induced lesions to different age Wistar rat brain mitochondria]]|| [[Arandarcikaite Odeta]] | ||
|- | |- | ||
|- | |- | ||
| || || 15:05 || | | || || 15:05 || TBC || | ||
|- | |- | ||
|- | |- | ||
| || || 15:10|| | | || || 15:10|| [[Meszaros 2022 Abstract Bioblast|Pre-transplant mitochondrial respiration as a clinical prognostic marker during static cold storage and machine perfusion of the liver]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 15:15 || | | || || 15:15 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 15:20 || | | || || 15:20 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 15:25 || | | || || 15:25 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
Line 101: | Line 101: | ||
|- | |- | ||
|- | |- | ||
| || || 16:30|| || | | || || 16:30|| [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 16:35|| || | | || || 16:35|| [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 16:40|| || | | || || 16:40|| [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 16:45|| || | | || || 16:45|| [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
Line 129: | Line 129: | ||
|- | |- | ||
|- | |- | ||
| || || 09:30 - 09:45 || [https://abliva.com/company/ Towards a treatment for mitochondrial disease: Current compounds in clinical development] || | | || || 09:30 - 09:45 || [https://abliva.com/company/ Towards a treatment for mitochondrial disease: Current compounds in clinical development] || [[]] | ||
|- | |- | ||
|- | |- | ||
Line 159: | Line 159: | ||
|- | |- | ||
|- | |- | ||
| || || 12:00 - 12:15 || | | || || 12:00 - 12:15 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 12:15 - 12:30 || | | || || 12:15 - 12:30 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
Line 183: | Line 183: | ||
|- | |- | ||
|- | |- | ||
| || || 15:00 - 15:15 || | | || || 15:00 - 15:15 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
| || || 15:15 - 15:30 || | | || || 15:15 - 15:30 || [[|]] || [[]] | ||
|- | |- | ||
|- | |- | ||
Line 199: | Line 199: | ||
|- | |- | ||
|- | |- | ||
| || || 16:00 - 16:15|| | | || || 16:00 - 16:15|| [[|]] || | ||
|- | |- | ||
|- | |- | ||
| || || 16:15 - 16:30 || | | || || 16:15 - 16:30 || [[|]] || | ||
|- | |- | ||
|- | |- | ||
| || || 16:30 - 16:45 || || | | || || 16:30 - 16:45 || [[|]] || | ||
|- | |- | ||
|- | |- | ||
| || || 16:45 - 17:00 || | | || || 16:45 - 17:00 || [[|]] || | ||
|- | |- | ||
|- | |- | ||
| || || 17:00 - 17:15 || | | || || 17:00 - 17:15 || [[|]] || | ||
|- | |- | ||
|- | |- | ||
| || || 17:15 - 17:30 || | | || || 17:15 - 17:30 || [[|]] || | ||
|- | |- | ||
|- | |- | ||
|} | |} |
Revision as of 09:27, 18 May 2022
Program
2022-06-29 Day 1 of scientific presentations
2022-06-30 Day 2 of scientific presentations